Palvella Therapeutics, Inc. Q4 FY2025 earnings call

2025 was a landmark year for Povella Therapeutics with several milestones achieved. Announced positive Phase II data in cutaneous venous malformations, surpassed target enrollment in phase three selva study in microcystic lymphatic malformations, expanded pipeline with two new programs, added top talent, extended collaboration with FDA, expanded IP portfolio, and secured fast-track designation for angiokeratomas. Corporate strategy focuses on serious rare diseases with no FDA-approved therapies, using proprietary cuturin platform. Microcystic lymphatic malformations program has positive Phase III data, on track for NDA submission and potential approval. Cutaneous venous malformations program has positive Phase II data, advancing to Phase III. Angiokeratomas program Phase II initiation moved up to Q2. DSAP program on track for Phase II initiation.

Microcystic lymphatic malformations program on track for NDA submission in second half of 2026 and potential FDA approval in first half of 2027. Cutaneous venous malformations program advancing to Phase III. Angiokeratomas program Phase II initiation in Q2. DSAP program Phase II initiation in second half of 2026.

Q: For the Q-Torrent Rapid License platform, what are the gating steps for each new indication that you choose to pursue?

A: Start with disease profiling, look for no FDA-approved therapies, low competitive intensity, clear biology, existing human proof-of-concept data.

Q: Will the Phase II extension data be part of breakthrough application for CVM?

A: Breakthrough application will include phase two data, patient qualitative interviews, and investigators' letter of support.

Q: Concerns about FDA unpredictability and one-armed study?

A: Interactions with FDA have been constructive, single-arm design valid due to no spontaneous regression, and macro trends work in favor.

Q: Plans for commercial launch beyond hires?

A: Building medical science liaison team, hiring sales reps, focusing on top 400 targets and medical meetings.

Q: Key endpoints in angiokeratoma Phase II study?

A: No pre-specified statistical hierarchy, look at various endpoints including individual signs, global endpoints, clinician and patient perspectives.

Q: Cash burn expectations?

A: Cash sufficient to get through programs, around $80 million cash burn in 2026.

Q: FDA flexibility on plausible mechanism pathway?

A: Not had formal interactions yet, monitoring and intention to evaluate.

Q: Drivers for angiokeratoma clinical initiation acceleration?

A: Fast-track designation, leveraging existing tox package and manufacturing process.

Q: Treatment compliance and adverse events?

A: Expected high compliance, minimal adverse events in trials.

Q: Pre-NDA meeting and age range?

A: Pre-NDA meeting to present data, age range discussion occurs later.

Q: Steps for platform technology designation?

A: Secure initial approval first, then work towards platform technology designation.

Q: Angiokeratoma patient recruitment and DSAP mechanism?

A: Leverage existing clinical site network, DSAP has genetic basis and translational data supporting mevalonate pathway inhibition.

Q: Phase II study details for DSAP and angiokeratomas?

A: DSAP trial design not finalized, angiokeratoma study moving ahead with mixed site recruitment.